How Novo Nordisk misread the US market for its weight loss sensation Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, leaving the Danish drugmaker in a more vulnerable position when rival Eli Lilly entered the market, six former employees involved in the discussions told Reuters.

#NovoNordisk #weightloss #Wegovy #launchreadiness #pricingstrategy #weightlossdrug #EliLilly #pharmaceuticalsupply #pharmaceuticalforecasting #launchpreparedness #pharmaceuticaldemand #pharmaceutcalsupplyshortages #Wegovysupplyissues #volumecappedlaunches
www.reuters.com/sustainabili...